With the Dec. 7 deadline for Medicare’s annual enrollment period fast approaching, Smart Insurance Company is working with Walgreens to offer in–store consultations with licensed SmartD Rx plan agents, available at select Walgreens to speak with Medicare beneficiaries who are either enrolling in a new Part D prescription drug plan or evaluating their current coverage options.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59273-smart-insurance-company-walgreens-smartd-rx-open-enrollment-ends-dec-7
In a revolutionary treatment for early-onset scoliosis (EOS), a team of surgeons implanted adjustable growing rods in two children from California. The pioneering surgeries — the first ever in the United States — were performed on May 7th at Rady Children’s Hospital in San Diego. The Food and Drug Administration (FDA) granted Compassionate Use approval to use the MAGEC™ (MAGnetic Expansion Control) System, developed by Ellipse Technologies, Inc., for these two patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61604-rady-children-s-hospital-san-diego-ellipse-magec-early-onset-scoliosis-eos
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
The Hall Oplum is not only a centre for learning. But also symbolic of the effarts of His Majesty king Bhumlbol Adulyadej and other members of the Royal Family to solve the problems of illicit drug production and durg addiction.ir is a testimony to their work that as of 2003, thailand was no longer considered by the United nations office on Durgs and Crime (UNODC) to be a signlflcant producer of oplum.
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy.
“With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Nonfiction – This is a true account – a memoir – of a single mother losing everything, including her 2 children, Jayden and Annie, to a wretched alcohol and drug addiction; and ultimately losing herself. Yet through the storm, she finds the strength to overcome this addiction, as a result gaining more than ever before. “Freedom has never been sweeter.” Though her story starts out in despair, it ends on a positive note, providing hope to all those that read it. Learn more about this book here, http://alisamassey.com Inspirational Christian memoir about overcoming personal obstacles (drugs and alcohol).
OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
